1 duplicate copy in the archive
EFTA Document EFTA01450727
Title Matchefta-efta01450727
Case Filesd-10-EFTA01450727Dept. of JusticeEFTA Document EFTA01450727
Unknown1p
Case File
sd-10-EFTA01450727Dept. of JusticeEFTA Document EFTA01450727
Other
Equity Research Healthcare I Biotechnology ARIAD Pharmaceuticals, Inc. Iclusig Comes Back With a New Label and REMS; Upgrade to Outperform and Increase Price Target to $12 On Friday, December 20, Ariad announced that it has reached agreement with the FDA for immediate reauthorization of Iclusig marketing in the United States, with a narrower label and accompanying Risk Mitigation Strategy (REMS) and post- marketing requirements (PMRs). Ariad plans to resume shipping of Iclusig by mid- Jan
Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01450727
Pages
1
Persons
0
Integrity
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.